GlobeNewswire by notified

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara

Share

BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 4 December 2023 at 4.45 p.m. (EET)

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara

____________________________________________

Person subject to the notification requirement

Name: Jalovaara Pekka

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20231203205051_6

____________________________________________

Transaction date: 2023-11-30

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000260583

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 126,606 Unit price: 0.005012 EUR

Aggregated transactions

(1): Volume: 126,606 Volume weighted average price: 0.005012 EUR

____________________________________________

Person subject to the notification requirement

Name: Jalovaara Pekka

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20231203205322_7

____________________________________________

Transaction date: 2023-12-01

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000260583

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 108,682 Unit price: 0.003187 EUR

Aggregated transactions

(1): Volume: 108,682 Volume weighted average price: 0.003187 EUR


For more information, please contact:

Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se


BBS in brief

BBS -Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sanoma Corporation - Managers' Transactions21.2.2024 08:15:00 CET | Press release

Sanoma Corporation, Managers’ Transactions, 21 February 2024 at 9:15 EET Sanoma Corporation - Managers' Transactions ___________________________________________ Person subject to the notification requirement Name: Holding Manutas Oy Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Anna Herlin Position: Member of the Board Issuer: Sanoma Oyj LEI: 743700XJC24THUPK0S03 Notification type: INITIAL NOTIFICATION Reference number: 52987/5/6 ____________________________________________ Transaction date: 2024-02-20 Venue: AQEU Instrument type: SHARE ISIN: FI0009007694 Nature of transaction: ACQUISITION Transaction details (1): Volume: 350 Unit price: 6.86 EUR (2): Volume: 3 Unit price: 6.87 EUR (3): Volume: 64 Unit price: 6.89 EUR (4): Volume: 88 Unit price: 6.93 EUR (5): Volume: 1 Unit price: 6.94 EUR (6): Volume: 350 Unit price: 6.99 EUR Aggregated transactions (6): Volume: 856 Volume weighted average price: 6.92272 EUR ___

CASH FLOW STRENGTHENED AND PROFITABILITY IMPROVED IN THE LAST QUARTER OF THE YEAR21.2.2024 08:15:00 CET | Press release

ROBIT PLC PRESS RELEASE 21 FEBRUARY 2024 AT 9.15 EET CASH FLOW STRENGTHENED AND PROFITABILITY IMPROVED IN THE LAST QUARTER OF THE YEAR Market demand weakened during 2023, which affected the construction industry in Europe and Asia in particular. Customer demand in the mining industry remained at a good level during the year, but the high stock levels of customers and distributors, and de-stocking, weakened Robit’s sales also in the mining industry. Robit’s net sales for 2023 declined by 17.0 percent to EUR 92.9 million (112.0). In constant currencies, the decline was 13.7 percent. A significant reason for the decreased sales was the closure of the Russian business, which had an 8.3 percent impact on the declined net sales. The company’s full-year EBITDA decreased from the 2022 level totaling EUR 5.0 million (8.9). Profitability was weak, especially in the early part of the year, but the company managed to improve it with the help of the austerity measures implemented during the year. I

Bavarian Nordic delivered record financial results in 202321.2.2024 08:13:33 CET | Press release

Preliminary 2023 results exceed the latest guidance and represent the best-ever financial result in the Company’s history driven by extraordinary growth in travel health and a surge in smallpox/mpox vaccine sales.2024 revenue of DKK 5,000-5,300 million and EBITDA of DKK 1,100-1,350 million expected.Focused R&D efforts to drive sustainable value creation within infectious diseases; discontinuing immuno-oncology projects.The Company will host three capital markets days during February. COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provides an update on its R&D priorities. The preliminary revenue in 2023 was DKK 7,062 million compared to DKK 3,151 million in 2022, thus exceeding the annual guidance of DKK 6,900 million. The improved revenue was driven by the Public Preparedness segment due to a surge in sales of smallpox/mpox vaccines followi

Bavarian Nordic leverede rekordresultat i 202321.2.2024 08:13:33 CET | pressemeddelelse

De foreløbige resultater for 2023 overstiger de seneste forventninger og udgør selskabets bedste økonomiske resultater nogensinde, hvilket er en følge af ekstraordinær vækst inden for rejsevacciner og en stigning i salget af koppe-/mpoxvacciner.I 2024 forventes en omsætning på DKK 5.000-5.300 mio. og EBITDA på DKK 1.100-1.350 mio.Fokuserede aktiviteter inden for forskning og udvikling skal drive langsigtet værdiskabelse; selskabet ophører udviklingen inden for immunonkologi.Selskabet afholder tre kapitalmarkedsdage i slutningen af februar. KØBENHAVN, Danmark, 21. februar 2024 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag foreløbige, ureviderede finansielle resultater for 2023 samt forventninger til 2024. Desuden opdaterer selskabet på dets prioriteter inden for forskning og udvikling. Den foreløbige omsætning i 2023 var DKK 7.062 mio. sammenlignet med DKK 3.151 mio. i 2022 og oversteg dermed forventningerne til året om en omsætning på DKK 6.900 mio. Den forbedrede omsætning v

Wolters Kluwer 2023 Full-Year Report21.2.2024 08:01:01 CET | Press release

Wolters Kluwer 2023 Full-Year Report Alphen aan den Rijn, February 21, 2024 – Wolters Kluwer, a global leader in professional information, software solutions and services, today releases its full-year 2023 results. Highlights Revenues €5,584 million, up 5% in constant currencies and up 6% organically.Recurring revenues (82% of total revenues) up 7% organically.Digital & services revenues (94% of total revenues) grew 6% organically.Expert solutions (58% of total revenues) grew 8% organically.Cloud software (16% of total revenues) grew 15% organically.Adjusted operating profit €1,476 million, up 6% in constant currencies.Adjusted operating profit margin up 30 basis points to 26.4%.Diluted adjusted EPS €4.55, up 10% overall and up 12% in constant currencies.Adjusted free cash flow €1,164 million, down 2% in constant currencies.Net-debt-to-EBITDA of 1.5x; return on invested capital (ROIC) improved to 16.8%.Proposed 2023 total dividend €2.08 per share, an increase of 15%.Share buybacks:Comp

HiddenA line styled icon from Orion Icon Library.Eye